{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:59:27Z","timestamp":1761947967776},"reference-count":68,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bcp.2014.03.013","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T13:45:44Z","timestamp":1396359944000},"page":"313-320","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vivo models of multiple myeloma (MM)"],"prefix":"10.1016","volume":"89","author":[{"given":"Eric","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.03.013_bib0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1084\/jem.17.4.482","article-title":"Transplantation of tissues to the embryo of foreign species","volume":"17","author":"Murphy","year":"1912","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.19.5.513","article-title":"Factors of resistance to heteroplastic tissue-grafting","volume":"19","author":"Murphy","year":"1914","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.73.4.461","article-title":"Heterologous transplantation of mammalian tumors","volume":"73","author":"Green","year":"1941","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1126\/science.88.2285.357","article-title":"Heterotransplantation of human and other mammalian tumors","volume":"88","author":"Green","year":"1938","journal-title":"Science"},{"key":"10.1016\/j.bcp.2014.03.013_bib0025","first-page":"611","article-title":"The heterotransplantation of human melanomas","volume":"22","author":"Green","year":"1950","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3181\/00379727-104-25987","article-title":"Growth of human cancer cells (HEp 2) in newborn rats","volume":"104","author":"Kutner","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0035","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/1097-0142(196611)19:11<1670::AID-CNCR2820191136>3.0.CO;2-V","article-title":"Growth of primary explants of human cancer in newborn rats","volume":"19","author":"Southam","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0304-3835(75)96769-5","article-title":"Human breast cancinoma: heterotransplantation to newborn rats","volume":"1","author":"Benjamin","year":"1976","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bcp.2014.03.013_bib0045","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1749-6632.1962.tb45319.x","article-title":"Role of the thymus in transplantation immunity","volume":"99","author":"Miller","year":"1962","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bcp.2014.03.013_bib0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S0016672300010168","article-title":"\u2018Nude\u2019, a new hairless gene with pleiotropic effects in the mouse","volume":"8","author":"Flanagan","year":"1966","journal-title":"Genet Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0055","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/217370a0","article-title":"Absence of thymus in a mouse mutant","volume":"217","author":"Pantelouris","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.03.013_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.03.013_bib0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1017\/S0022172400010111","article-title":"The relative potency of carcinogenic tars and oils","volume":"29","author":"Twort","year":"1929","journal-title":"J Hyg"},{"key":"10.1016\/j.bcp.2014.03.013_bib0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S0022172400011086","article-title":"The fate of mineral oils injected into the peritoneal cavity of mice","volume":"38","author":"Twort","year":"1937","journal-title":"J Hyg"},{"key":"10.1016\/j.bcp.2014.03.013_bib0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/bjc.1950.10","article-title":"On the susceptibility of the thymus, lung, subcutaneous and mammary tumors in strain street mice to direct application of small doses of four different carcinogenic hydrocarbons","volume":"4","author":"Rask-Nielsen","year":"1950","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bjc.1950.11","article-title":"Types of tumors in the lungs of strain street mice following direct application of large doses of four different carcinogenic hydrocarbons","volume":"4","author":"Rask-Nielsen","year":"1950","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3181\/00379727-101-24970","article-title":"Induction of plasma cell neoplasms and fibrosarcomas in BALB\/c mice carrying diffusion chambers","volume":"101","author":"Merwin","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0090","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/222994a0","article-title":"Induction of plasma cell tumours in BALB\/c mice with 2,6,1014-tetramethylpentadecane (pristine)","volume":"222","author":"Anderson","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.03.013_bib0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0889-8588(05)70434-2","article-title":"Experimental plasmacytomagenesis in mice","volume":"11","author":"Potter","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bcp.2014.03.013_bib0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augument natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0609.2005.00427.x","article-title":"The bisphosphate zoledronic acid inhibits the development of plasmacytoma induced in BALB\/c mice by intraperitoneal injection of pristane","volume":"74","author":"Avcu","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0110","first-page":"586a","article-title":"Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases","volume":"88","author":"Berenson","year":"1996","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.bcp.2014.03.013_bib0115","first-page":"S485","article-title":"A dose finding study of zoledronate intravenous infusion in patients with tumor induced hypercalcemia","volume":"11","author":"Body","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0120","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasis","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0125","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastasis","volume":"7","author":"Berenson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy\u2013a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomized controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0140","first-page":"191","article-title":"Spontaneous multiple myeloma with bone lesions in the C57BL\/KaLwRij mouse as a natural model of human disease. Monoclonal gammapathies, clinical significance and basic mechanisms","volume":"Vol. 5","author":"Radl","year":"1985"},{"key":"10.1016\/j.bcp.2014.03.013_bib0145","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2014.03.013_bib0150","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","article-title":"Influence of treatment with ADP-bisphosphanate on the bone lesions in the mouse 5T2 multiple myeloma","volume":"55","author":"Radl","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0155","series-title":"Experimental approaches to the treatment of multiple myeloma, studies in an animal model [dissertation]","author":"Croese","year":"1987"},{"key":"10.1016\/j.bcp.2014.03.013_bib0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2014.03.013_bib0165","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0170","doi-asserted-by":"crossref","first-page":"160a","DOI":"10.1182\/blood.V98.13.3534","article-title":"Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0175","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-Bearing mice inhibits the development of myeloma bone disease: evidence of decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2014.03.013_bib0185","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1073\/pnas.022643999","article-title":"IL-6 transgenic mouse model for extraosseous plasmacytoma","volume":"99","author":"Kovalchuk","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2014.03.013_bib0190","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/0008-5472.CAN-06-1561","article-title":"Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells","volume":"67","author":"Qi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0195","first-page":"8656","article-title":"BCL2 accelerates inflammation-induced BALB\/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations","volume":"63","author":"Silva","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0200","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI200420369","article-title":"Novel targeted deregulation c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice","volume":"113","author":"Cheung","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.03.013_bib0205","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies","volume":"17","author":"Lee","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood.V120.21.332.332","article-title":"A phase \u00bd study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0215","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0220","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I pharmacologic study of SNS-032, a potent and selective, Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0225","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2014.03.013_bib0235","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2003-01-0016","article-title":"Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis","volume":"102","author":"Davies","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0240","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1699-0463.1969.tb04520.x","article-title":"Heterotransplantation of a human malignant tumor to nude mice","volume":"77","author":"Raygaard","year":"1969","journal-title":"Acta Path Microbiol Scand"},{"key":"10.1016\/j.bcp.2014.03.013_bib0245","first-page":"593","article-title":"Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice","volume":"13","author":"Tong","year":"1993","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2014.03.013_bib0250","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood.V80.11.2843.2843","article-title":"Long-term engraftment of fresh human myeloma cells in SCID","volume":"80","author":"Feo-Zuppardi","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0255","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V90.2.754","article-title":"The development of a model for the homing of multiple myeloma cells to human bone marrow","volume":"90","author":"Urashima","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0260","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/0471141755.ph1409s40","article-title":"Animal models of multiple myeloma and their utility in drug discovery","volume":"40","author":"Campbell","year":"2008","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0270","first-page":"1409","article-title":"LAG\u03bb-1: a clinically relevant drug resistant human multiple myeloma tumor murine model enables rapid evaluation of treatments for multiple myeloma","volume":"28","author":"Campbell","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0275","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/480S38a","article-title":"Animal models: towards a myeloma mouse","volume":"480","author":"DeWeerdt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.03.013_bib0280","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-010-1052-8","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma","volume":"90","author":"Waterman","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0285","doi-asserted-by":"crossref","first-page":"239a","DOI":"10.1182\/blood.V108.11.797.797","article-title":"Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with multiple myeloma: Cancer Leukemia Group B study 10301","volume":"108","author":"Orlowski","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.03.013_bib0290","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0295","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2011.08884.x","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients","volume":"155","author":"Beresnon","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2014.03.013_bib0305","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt0610-561","article-title":"Raising the bar for cancer therapy models","volume":"28","author":"Francia","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0310","first-page":"289","article-title":"Different growth rates of lung tumors in man and their xenografts in nude mice","volume":"46","author":"Mattern","year":"1979","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0315","series-title":"Proceedings of third international workshop on nude mice","first-page":"447","article-title":"Analysis of human tumor growth in nude mice","author":"Fogh","year":"1982"},{"key":"10.1016\/j.bcp.2014.03.013_bib0320","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ijc.2910470113","article-title":"Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the her-2\/neu oncogene","volume":"47","author":"Giovanella","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bcp.2014.03.013_bib0325","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.4049\/jimmunol.109.6.1193","article-title":"Immunocytology of cultured IgM-forming cells of mouse. I. Requirement of phagocytic cell factor for the growth of IgM-forming tumor cells in tissue culture","volume":"109","author":"Namba","year":"1972","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0330","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0008-8749(74)90058-6","article-title":"Immunocytology of cultured IgM-forming cells of mouse. II. Purification of phagocytic cell factor and its role in antibody formation","volume":"12","author":"Namba","year":"1974","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bcp.2014.03.013_bib0335","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Hildago","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2014.03.013_bib0340","first-page":"3759","article-title":"Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts","volume":"49","author":"Kallinowski","year":"1989","journal-title":"Cancer Res"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214002007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214002007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:18:53Z","timestamp":1689099533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214002007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0006295214002007"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.03.013","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo models of multiple myeloma (MM)","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}